These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

278 related items for PubMed ID: 17045785

  • 1. Activity of tigecycline against clinical isolates of Staphylococcus aureus and extended-spectrum beta-lactamase-producing Escherichia coli in Granada, Spain.
    Sorlózano A, Gutiérrez J, Salmerón A, Luna JD, Martínez-Checa F, Román J, Piédrola G.
    Int J Antimicrob Agents; 2006 Dec; 28(6):532-6. PubMed ID: 17045785
    [Abstract] [Full Text] [Related]

  • 2. Determination of the pharmacodynamic activity of clinically achievable tigecycline serum concentrations against clinical isolates of Escherichia coli with extended-spectrum beta-lactamases, AmpC beta-lactamases and reduced susceptibility to carbapenems using an in vitro model.
    Zhanel GG, Baudry PJ, Tailor F, Cox L, Hoban DJ, Karlowsky JA.
    J Antimicrob Chemother; 2009 Oct; 64(4):824-8. PubMed ID: 19643776
    [Abstract] [Full Text] [Related]

  • 3. In vitro activity of cefepime, imipenem, tigecycline, and gentamicin, alone and in combination, against extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
    Cha R.
    Pharmacotherapy; 2008 Mar; 28(3):295-300. PubMed ID: 18294108
    [Abstract] [Full Text] [Related]

  • 4. Antimicrobial susceptibility of well-characterised multiresistant CTX-M-producing Escherichia coli: failure of automated systems to detect resistance to piperacillin/tazobactam.
    Pitout JD, Le P, Church DL, Gregson DB, Laupland KB.
    Int J Antimicrob Agents; 2008 Oct; 32(4):333-8. PubMed ID: 18701262
    [Abstract] [Full Text] [Related]

  • 5. Other antimicrobials of interest in the era of extended-spectrum beta-lactamases: fosfomycin, nitrofurantoin and tigecycline.
    Garau J.
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():198-202. PubMed ID: 18154548
    [Abstract] [Full Text] [Related]

  • 6. Antimicrobial susceptibility of extended-spectrum beta-lactamase producers and multidrug-resistant Acinetobacter baumannii throughout the United States and comparative in vitro activity of tigecycline, a new glycylcycline antimicrobial.
    Hoban DJ, Bouchillon SK, Dowzicky MJ.
    Diagn Microbiol Infect Dis; 2007 Apr; 57(4):423-8. PubMed ID: 17403448
    [Abstract] [Full Text] [Related]

  • 7. Nationwide surveillance in Taiwan of the in-vitro activity of tigecycline against clinical isolates of extended-spectrum beta-lactamase-producing Enterobacteriaceae.
    Lu CT, Chuang YC, Sun W, Liu YC, Cheng YJ, Lu PL, Chen CM, Hsu GJ, Jang TN, Lee CM, Chiang PC, Shi ZY, Wang LS, Kung HC, Lin HC, Liao CH, Liu JW, Huang CH, Tsao SM, Hsueh PR.
    Int J Antimicrob Agents; 2008 Nov; 32 Suppl 3():S179-83. PubMed ID: 19013351
    [Abstract] [Full Text] [Related]

  • 8. In vitro activity of tigecycline against extended-spectrum β-lactamase-producing Enterobacteriaceae and MRSA clinical isolates from Mexico: a multicentric study.
    Silva-Sanchez J, Reyna-Flores F, Velazquez-Meza ME, Rojas-Moreno T, Benitez-Diaz A, Sanchez-Perez A, Study Group.
    Diagn Microbiol Infect Dis; 2011 Jun; 70(2):270-3. PubMed ID: 21596226
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. In vitro activity of beta-lactam and non-beta-lactam antibiotics in extended-spectrum beta-lactamase-producing clinical isolates of Escherichia coli.
    Puerto AS, Fernández JG, del Castillo Jde D, Pino MJ, Angulo GP.
    Diagn Microbiol Infect Dis; 2006 Feb; 54(2):135-9. PubMed ID: 16406187
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Update on antimicrobial susceptibility rates among gram-negative and gram-positive organisms in the United States: results from the Tigecycline Evaluation and Surveillance Trial (TEST) 2005 to 2007.
    Dowzicky MJ, Park CH.
    Clin Ther; 2008 Nov; 30(11):2040-50. PubMed ID: 19108792
    [Abstract] [Full Text] [Related]

  • 13. In vitro activity of tigecycline against quinolone-resistant Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci.
    Garrison MW, Nuemiller JJ.
    Int J Antimicrob Agents; 2007 Feb; 29(2):191-6. PubMed ID: 17174074
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Effect of certain bioactive plant extracts on clinical isolates of beta-lactamase producing methicillin resistant Staphylococcus aureus.
    Aqil F, Khan MS, Owais M, Ahmad I.
    J Basic Microbiol; 2005 Feb; 45(2):106-14. PubMed ID: 15812867
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. In vitro activity of tigecycline against clinical isolates of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae, Serratia marcescens and Enterobacter cloacae.
    Ku YH, Chuang YC, Yu WL.
    J Microbiol Immunol Infect; 2008 Aug; 41(4):332-6. PubMed ID: 18787741
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. First report of the emergence of CTX-M-type extended-spectrum beta-lactamases (ESBLs) as the predominant ESBL isolated in a U.S. health care system.
    Lewis JS, Herrera M, Wickes B, Patterson JE, Jorgensen JH.
    Antimicrob Agents Chemother; 2007 Nov; 51(11):4015-21. PubMed ID: 17724160
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.